A randomized placebo-controlled clinical trial for pharmacological activation of BCAA catabolism in patients with type 2 diabetes

Froukje Vanweert, Michael Neinast, Edmundo Erazo Tapia, Tineke Weijer, Joris Hoeks, Vera B. Schrauwen-Hinderling, Megan C. Blair, Marc R. Bornstein, Matthijs K. C. Hesselink, Patrick Schrauwen, Zoltan Arany and Esther Phielix ()
Additional contact information
Froukje Vanweert: Maastricht University
Michael Neinast: University of Pennsylvania, Philadelphia
Edmundo Erazo Tapia: Maastricht University
Tineke Weijer: Maastricht University
Joris Hoeks: Maastricht University
Vera B. Schrauwen-Hinderling: Maastricht University
Megan C. Blair: University of Pennsylvania, Philadelphia
Marc R. Bornstein: University of Pennsylvania, Philadelphia
Matthijs K. C. Hesselink: Maastricht University
Patrick Schrauwen: Maastricht University
Zoltan Arany: University of Pennsylvania, Philadelphia
Esther Phielix: Maastricht University

Nature Communications, 2022, vol. 13, issue 1, 1-9

Abstract: Abstract Elevations in plasma branched-chain amino acid (BCAA) levels associate with insulin resistance and type 2 diabetes (T2D). Pre-clinical models suggest that lowering BCAA levels improve glucose tolerance, but data in humans are lacking. Here, we used sodium phenylbutyrate (NaPB), an accelerator of BCAA catabolism, as tool to lower plasma BCAA levels in patients with T2D, and evaluate its effect on metabolic health. This trial (NetherlandsTrialRegister: NTR7426) had a randomized, placebo-controlled, double-blind cross-over design and was performed in the Maastricht University Medical Center (MUMC+), the Netherlands, between February 2019 and February 2020. Patients were eligible for the trial if they were 40–75years, BMI of 25–38 kg/m², relatively well-controlled T2D (HbA1C

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-31249-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31249-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-31249-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().